Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate the safety and tolerability of different regimens of IMO-2125 in combination with ribavirin compared to PegasysTM plus ribavirin administered for 12 weeks to patients with chronic HCV infection who were nonresponders to prior treatment with pegylated-interferon plus ribavirin.
Critère d'inclusion
- This is a Phase 2, randomized, double-blind, comparator-controlled study of IMO-2125 in hepatitis C-infected patients who were previously nonresponders to standard treatment (pegylated-interferon plus ribavirin) – that is, were treated at least 12 weeks and never achieved an undetectable viral load during or at the end of treatment. The population under study is nonresponder patients with chronic hepatitis C virus (HCV) infection